Payment overview · 2025
General Payments
$540.32
22 reported records · 7 companies
Healthcare provider profile · identity verified
Kirit S Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Addiction Medicine · SHREVEPORT, LA · NPI 1477512309
Verified facts
What the public records show
CMS Open Payments records show Kirit S Patel, M.D. received $540.32 in general payments during 2025 across 22 reported records.
Phathom Pharmaceuticals, Inc. accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $184.96 | 34.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.97 | 31.8% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.09 | 12.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.62 | 7.3% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $29.52 | 5.5% | 1 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $27.59 | 5.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.57 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $540.32 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $184.96 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.35 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $84.74 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $68.09 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.62 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.62 | 2 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 51 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
258 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
107 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 341 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 260 | 58 |
| Eliquis | Apixaban | 258 | 32 |
| Gabapentin | Gabapentin | 240 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 49 |
| Losartan Potassium | Losartan Potassium | 159 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 28 |
| Potassium Chloride | Potassium Chloride | 150 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 36 |
| Metformin Hcl | Metformin Hcl | 139 | 43 |
| Meloxicam | Meloxicam | 136 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 30 |
| Nifedipine Er | Nifedipine | 122 | 32 |
| Famotidine | Famotidine | 117 | 17 |
| Jardiance | Empagliflozin | 114 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 22 |
| Lisinopril | Lisinopril | 104 | 19 |
| Carvedilol | Carvedilol | 98 | 23 |
| Furosemide | Furosemide | 98 | 28 |
| Donepezil Hcl | Donepezil Hcl | 89 | 18 |
| Sertraline Hcl | Sertraline Hcl | 87 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 81 | 29 |
| Trazodone Hcl | Trazodone Hcl | 74 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 17 |
| Omeprazole | Omeprazole | 71 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 17 |
| Entresto | Sacubitril/Valsartan | 60 | suppressed |
| Baclofen | Baclofen | 59 | suppressed |
| Simvastatin | Simvastatin | 59 | 13 |
| Farxiga | Dapagliflozin Propanediol | 58 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 18 |
| Montelukast Sodium | Montelukast Sodium | 55 | 13 |
| Olanzapine | Olanzapine | 54 | suppressed |
| Bumetanide | Bumetanide | 52 | suppressed |
| Ozempic | Semaglutide | 52 | 11 |
| Prednisone | Prednisone | 52 | 19 |
| Rybelsus | Semaglutide | 51 | 11 |
| Allopurinol | Allopurinol | 50 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 11 |
| Tramadol Hcl | Tramadol Hcl | 49 | 15 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Memantine Hcl | Memantine Hcl | 47 | 14 |
| Methocarbamol | Methocarbamol | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 39 | 39 |
| Alprazolam | Alprazolam | 39 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 38 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 12 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 13 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 18 |
| Mitigare | Colchicine | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Diazepam | Diazepam | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Humulin R | Insulin Regular, Human | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Armodafinil | Armodafinil | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Meropenem | Meropenem | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $540.32 · 22 records | Phathom Pharmaceuticals, Inc. | AIRSUPRA, AREXVY, ARTIX MT, COBENFY, FARXIGA, Ozempic, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Zunveyl | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error